Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Lymphoma, Follicular 1Dermatitis, Atopic 1Colorectal Neoplasms 1

Interventions

Rituximab 302Cyclophosphamide 242Peripheral Blood Stem Cell Transplantation 115fludarabine phosphate 111Filgrastim 93Etoposide 85Radiotherapy 81Lenalidomide 81Vincristine 80Prednisone 80Mycophenolic Acid 67Doxorubicin 63Bendamustine Hydrochloride 60Whole-Body Irradiation 59Cyclosporine 59Melphalan 57Tacrolimus 54Busulfan 52obinutuzumab 50fludarabine 50Cytarabine 49Methotrexate 45Antilymphocyte Serum 43Bortezomib 42Methylprednisolone 37Carmustine 37sargramostim 36ibritumomab tiuxetan 33ibrutinib 30Dexamethasone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × dupilumab × Clear all
NCT03736967 2021-11-01

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Regeneron Pharmaceuticals

Phase 2 Terminated
206 enrolled 34 charts
Lymphoid

Dermatitis, Atopic, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡